专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005123736A8 NOVEL 2-BENZYLAMINODIHYDROPTERIDINONES, METHOD FOR PRODUCING THEM AND USE THEREOF AS DRUGS 审中-公开
标题翻译：新的2 BENZYLAMINODIHYDROPTERIDINONE，方法及其及其作为药物
公开(公告)号：WO2005123736A8
公开(公告)日：2006-03-30
申请号：PCT/EP2005006404
申请日：2005-06-15
申请人： BOEHRINGER INGELHEIM INT , BOEHRINGER INGELHEIM PHARMA , HOFFMANN MATTHIAS , STEEGMAIER MARTIN , GRAUERT MATTHIAS , LEHMANN-LINTZ THORSTEN , REDEMANN NORBERT , SOLCA FLAVIO
发明人： HOFFMANN MATTHIAS , STEEGMAIER MARTIN , GRAUERT MATTHIAS , LEHMANN-LINTZ THORSTEN , REDEMANN NORBERT , SOLCA FLAVIO
IPC分类号： A61K31/519 , A61P35/00 , C07D475/00
CPC分类号： C07D475/00
摘要： The invention relates to the novel 2-benzylaminodihydropteridinones of general formula (I), wherein the groups R
摘要翻译：本发明涉及新的2- Benzylaminodihydropteridinone通式（I）其中基团R1至R7，R10和R11具有权利要求书和说明书中给出的含义，它们的异构体，制备这些二氢喋啶酮和作为药物中的用途的处理。

2. 发明申请

WO2006021378A8 DIHYDROPTERIDINONE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS 审中-公开
标题翻译： DIHYDROPTERIDINONDERIVATE，方法及其及其作为药物
公开(公告)号：WO2006021378A8
公开(公告)日：2006-04-27
申请号：PCT/EP2005008990
申请日：2005-08-19
申请人： BOEHRINGER INGELHEIM INT , BOEHRINGER INGELHEIM PHARMA , GRAUERT MATTHIAS , HOFFMANN MATTHIAS , STEEGMAIER MARTIN , EICKMEIER CHRISTIAN , SCHNAPP GISELA , REDEMANN NORBERT , SOLCA FLAVIO , QUANT JENS JUERGEN
发明人： GRAUERT MATTHIAS , HOFFMANN MATTHIAS , STEEGMAIER MARTIN , EICKMEIER CHRISTIAN , SCHNAPP GISELA , REDEMANN NORBERT , SOLCA FLAVIO , QUANT JENS JUERGEN
IPC分类号： C07D475/04 , A61K31/4375 , A61P35/00
CPC分类号： C07D487/04 , C07D475/00 , Y02P20/55
摘要： The invention relates to novel dihydropteridinones of general formula (I), in which the radicals L, R
摘要翻译：本发明涉及通式（I）中，新颖的二氢喋啶酮其中基团L，R

3. 发明申请

WO2006021379A8 DIHYDROPTERIDINONE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS 审中-公开
标题翻译：二氢蝶啶酮衍生物，其制备方法及其作为药物的用途
公开(公告)号：WO2006021379A8
公开(公告)日：2006-04-27
申请号：PCT/EP2005008991
申请日：2005-08-19
申请人： BOEHRINGER INGELHEIM INT , BOEHRINGER INGELHEIM PHARMA , GRAUERT MATTHIAS , HOFFMANN MATTHIAS , STEEGMAIER MARTIN , SOLCA FLAVIO , QUANT JENS JUERGEN
发明人： GRAUERT MATTHIAS , HOFFMANN MATTHIAS , STEEGMAIER MARTIN , SOLCA FLAVIO , QUANT JENS JUERGEN
IPC分类号： C07D475/04 , A61K31/4375 , A61P35/00
CPC分类号： C07D295/155 , C07D487/04 , Y02P20/55
摘要： The invention relates to novel dihydropteridinones of general formula (I), in which the radicals L, R
摘要翻译：本发明涉及通式（I）的新的二氢喋啶酮，其中基团L，R

4. 发明申请

WO2006008028A8 NOVEL 6-FORMYLTETRAHYDROPTERIDINES METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT AGAINST CANCER AMONGST OTHER THINGS 审中-公开
标题翻译：新的6-甲酰基 - 四氢蝶啶，其制备方法以及它们作为药物的用途，U.A. 反对癌症
公开(公告)号：WO2006008028A8
公开(公告)日：2006-03-30
申请号：PCT/EP2005007532
申请日：2005-07-12
申请人： BOEHRINGER INGELHEIM INT , BOEHRINGER INGELHEIM PHARMA , HOFFMANN MATTHIAS , GRAUERT MATTHIAS , STEEGMAIER MARTIN , SOLCA FLAVIO
发明人： HOFFMANN MATTHIAS , GRAUERT MATTHIAS , STEEGMAIER MARTIN , SOLCA FLAVIO
IPC分类号： C07D475/00 , A61K31/519
CPC分类号： C07D475/00
摘要： The invention relates to novel 6-formyltetrahydropteridines of general formula (I), where the groups R
摘要翻译：本发明涉及其中基团R

5. 发明申请

WO2005113515A8 PYRIMIDINES FOR USE AS PLK INHIBITORS 审中-公开
标题翻译：嘧啶，其PLK抑制剂
公开(公告)号：WO2005113515A8
公开(公告)日：2006-11-02
申请号：PCT/EP2005052214
申请日：2005-05-13
申请人： BOEHRINGER INGELHEIM INT , BOEHRINGER INGELHEIM PHARMA , STADTMUELLER HEINZ , ENGELHARDT HARALD , REISER ULRICH , ZAHN STEPHAN KARL , HAUPTMANN RUDOLF , STEEGMAIER MARTIN , GUERTLER ULRICH , HOFFMANN MATTHIAS , GRAUERT MATTHIAS
发明人： STADTMUELLER HEINZ , ENGELHARDT HARALD , REISER ULRICH , ZAHN STEPHAN KARL , HAUPTMANN RUDOLF , STEEGMAIER MARTIN , GUERTLER ULRICH , HOFFMANN MATTHIAS , GRAUERT MATTHIAS
IPC分类号： C07D239/48 , A61K31/505 , A61P29/00 , A61P31/12 , A61P35/00 , A61P37/00 , C07D401/12 , C07D403/12
CPC分类号： C07D239/48 , C07D401/12 , C07D403/12
摘要： The invention relates to the compounds of formula (1), wherein A, X, Y, Z, R a , R b , R c , R 1 , R 2 and R 3 are defined as in claim 1. These compounds are suitable for use in the treatment of diseases which are characterized by excessive or abnormal cell proliferation. The invention also relates to the use of these compounds in the production of a drug having the above-mentioned properties.
摘要翻译：本发明包括通式（1）化合物，其中A，X，Y，Z，R ^{一，R ^{B'/ SUP>，R ^{C ，R ^{1 ，R ^{2 和R ^{3 是如权利要求1中所定义，对于疾病的治疗特征为过度或异常细胞增殖的是合适的，并且其用于生产具有上述特性的药物。}}}}}}

6. 发明申请

WO2007115931A8 THIAZOLYLDIHYDROCYCLOPENTAPYRAZOLES FOR USE AS PI3-KINASE INHIBITORS 审中-公开
标题翻译：噻唑二氢 - 环戊FOR USE AS PI3激酶INHIBIT0REN
公开(公告)号：WO2007115931A8
公开(公告)日：2008-06-12
申请号：PCT/EP2007052914
申请日：2007-03-27
申请人： BOEHRINGER INGELHEIM INT , BOEHRINGER INGELHEIM PHARMA , BREITFELDER STEFFEN , MAIER UDO , HOENKE CHRISTOPH , JOERGENSEN ANNE T , PAUTSCH ALEXANDER , BRANDL TRIXI , GRAUERT MATTHIAS , HOFFMANN MATTHIAS , SCHEUERER STEFAN , ERB KLAUS , PIEPER MICHAEL , PRAGST INGO
发明人： BREITFELDER STEFFEN , MAIER UDO , HOENKE CHRISTOPH , JOERGENSEN ANNE T , PAUTSCH ALEXANDER , BRANDL TRIXI , GRAUERT MATTHIAS , HOFFMANN MATTHIAS , SCHEUERER STEFAN , ERB KLAUS , PIEPER MICHAEL , PRAGST INGO
IPC分类号： A61K31/429 , A61P11/00 , A61P35/00 , C07D513/04
CPC分类号： C07D513/04
摘要： The present invention relates to compounds of the general formula (I), where the radicals R 1 , R 2 , R a and R b have the meanings specified in the claims and the description, their tautomers, racemates, enantiomers, diastereomers and their mixtures, and optionally their pharmacologically acceptable acid addition salts, solvates and hydrates, and to processes for the preparation of these thiazolyldihydrocyclopentapyrazoles and their use as medicaments.
摘要翻译：本发明涉及通式（I），其中基团R ^{1 ，R ^{2 ，R ^{一和R ^{b所示的化合物具有权利要求书和说明书中的所谓的含义onssalze其互变异构体，外消旋体，对映体，非对映体和它们的混合物，和任选的药学上可接受的Säureadditi-，溶剂合物和水合物，以及用于制备这些噻唑基 - dihydrocyclopentapyrazole 和它们作为药物的用途。}}}}

7. 发明申请

WO2007115929A8 THIAZOLYL-DIHYDROQUINAZOLINES 审中-公开
标题翻译：噻二氢喹唑啉
公开(公告)号：WO2007115929A8
公开(公告)日：2008-06-19
申请号：PCT/EP2007052912
申请日：2007-03-27
申请人： BOEHRINGER INGELHEIM INT , BOEHRINGER INGELHEIM PHARMA , BRANDL TRIXI , MAIER UDO , HOFFMANN MATTHIAS , SCHEUERER STEFAN , JOERGENSEN ANNE T , PAUTSCH ALEXANDER , BREITFELDER STEFFEN , GRAUERT MATTHIAS , HOENKE CHRISTOPH , ERB KLAUS , PIEPER MICHAEL , PRAGST INGO
发明人： BRANDL TRIXI , MAIER UDO , HOFFMANN MATTHIAS , SCHEUERER STEFAN , JOERGENSEN ANNE T , PAUTSCH ALEXANDER , BREITFELDER STEFFEN , GRAUERT MATTHIAS , HOENKE CHRISTOPH , ERB KLAUS , PIEPER MICHAEL , PRAGST INGO
IPC分类号： C07D513/04 , A61K31/429 , A61P29/00
CPC分类号： C07D513/04
摘要： The invention relates to novel thiazolyl-dihydroquinazolines of general formula (I), wherein the groups R 1 to R 4 are defined as in the claims and in the description, and to the isomers thereof. The invention also relates to methods for producing said thiazolyl-dihydroindazoles and to their use as drugs.
摘要翻译：本发明涉及通式（I）的新的噻唑二氢喹唑啉其中R ^{1 至R ^{4 具有权利要求书和说明书中给出的含义，所述异构体，以及制备这些噻唑基二氢吲唑和它们作为药物的用途。}}

8. 发明申请

WO2006018222A8 HYDRATES AND POLYMORPHS OF 4-[[(7R)-8-CYCLOPENTYL-7-ETHYL-5,6,7,8-TETRAHYDRO-5-METHYL-4-6-OXO-2-PIPERIDINYL]AMINO]-3-METHOXY-N-(1-METHYL-4-PIPERIDINYL) BENZAMIDE, METHODS FOR THE PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS 审中-公开
标题翻译：水合物和4的多晶型物 - [[（7R）-8-环戊基-7-乙基-5,6,7,8-四氢-5-甲基4-6-氧代-2-哌啶基]氨基] -3-甲氧基 -N-（1-甲基-4-哌啶基） - 苯甲酰胺，其制备方法及其作为药物的用途
公开(公告)号：WO2006018222A8
公开(公告)日：2006-06-15
申请号：PCT/EP2005008736
申请日：2005-08-11
申请人： BOEHRINGER INGELHEIM INT , BOEHRINGER INGELHEIM PHARMA , LINZ GUENTER , SIEGER PETER , KRAEMER GERD F , RALL WERNER , HERTER ROLF , HOFFMANN MATTHIAS , SCHMID ROLF
发明人： LINZ GUENTER , SIEGER PETER , KRAEMER GERD F , RALL WERNER , HERTER ROLF , HOFFMANN MATTHIAS , SCHMID ROLF
IPC分类号： C07D475/00 , A61K31/519 , A61P35/00 , C07D211/58
CPC分类号： C07D211/58 , C07D475/00
摘要： The invention relates to novel hydrates and novel polymorphs of 4-[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl) benzamide, methods for the production thereof, and the use thereof as medicaments.
摘要翻译：本发明涉及新的水合物和新的多晶型4 - [[（7R）-8-环戊基-7-乙基-5,6,7,8-四氢-5-甲基-6-氧代-2-蝶啶基]氨基] 3-甲氧基-N-（1-甲基-4-哌啶基）苯甲酰胺，它们的制备方法和它们作为药物的用途。

9. 发明申请

WO2010115836A1 SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS 审中-公开
标题翻译：作为CCR3拮抗剂的取代的哌啶
公开(公告)号：WO2010115836A1
公开(公告)日：2010-10-14
申请号：PCT/EP2010054396
申请日：2010-04-01
申请人： BOEHRINGER INGELHEIM INT , GRUNDL MARC , DOLLINGER HORST , GIOVANNINI RICCARDO , HOENKE CHRISTOPH , HOFFMANN MATTHIAS , KRIEGL JAN , MARTYRES DOMNIC , RAST GEORG , SEITHER PETER
发明人： GRUNDL MARC , DOLLINGER HORST , GIOVANNINI RICCARDO , HOENKE CHRISTOPH , HOFFMANN MATTHIAS , KRIEGL JAN , MARTYRES DOMNIC , RAST GEORG , SEITHER PETER
IPC分类号： C07D401/04 , A61K31/4523 , A61K31/454 , A61P31/00 , A61P35/00 , A61P37/00 , C07D401/14 , C07D413/04 , C07D413/14 , C07D417/14
CPC分类号： C07D401/04 , A61K31/4523 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/506 , A61K31/5355 , A61K31/56 , C07D401/14 , C07D413/04 , C07D413/14 , C07D417/14
摘要： Object of the present invention are novel substituted compounds of the formula 1, wherein A, R1, R2, R3 and R4 are defined as in the description. Another object of the present invention is to provide antagonists of CCR3, more particularly to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.
摘要翻译：本发明的目的是式I的新型取代化合物，其中A，R 1，R 2，R 3和R 4如说明书中所定义。本发明的另一目的是提供CCR3的拮抗剂，更具体地说是提供包含药学上可接受的载体和治疗有效量的至少一种本发明化合物或其药学上可接受的盐的药物组合物。

10. 发明申请

WO2010015518A2 4-DIMETHYLAMINO-PHENYL-SUBSTITUTED NAPHTHYRIDINES, AND USE THEREOF AS MEDICAMENTS 审中-公开
标题翻译： 4二甲氨基 - 取代萘啶及其作为药物
公开(公告)号：WO2010015518A2
公开(公告)日：2010-02-11
申请号：PCT/EP2009059493
申请日：2009-07-23
申请人： BOEHRINGER INGELHEIM INT , FIEGEN DENNIS , HANDSCHUH SANDRA , HOBBIE SILKE , HOFFMANN MATTHIAS , KONO TAKESHI , SATO YAYOI , SCHNAPP ANDREAS , SCHULER-METZ ANNETTE
发明人： FIEGEN DENNIS , HANDSCHUH SANDRA , HOBBIE SILKE , HOFFMANN MATTHIAS , KONO TAKESHI , SATO YAYOI , SCHNAPP ANDREAS , SCHULER-METZ ANNETTE
IPC分类号： C07D471/04 , A61K31/4375 , A61P11/06 , C07D519/00
CPC分类号： C07D471/04 , C07D519/00
摘要： The invention relates to novel substituted naphthyridines of formula 1 as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates, or solvates thereof. In formula 1, R1 can represent a group A selected from among the group comprising -O-R3, -NR3 R4, -CR3 R4 R5,-(ethyne)-R3, -S-R3, -SO-R3, and SO2 -R3, or R1 represents a group B selected from among the group comprising: - C6-10-aryl; - a five-membered to ten-membered, monocyclic or bicyclic heteroaryl containing 1 to 3 heteroatoms independently selected from among the group comprising N, O, and S, wherein said heteroaryl is linked to the structure according to formula 1 via a C atom or an N atom; - a three-membered to ten-membered, monocyclic or bicyclic, saturated or partially saturated heterocycle containing 1 to 3 heteroatoms independently selected from among the group comprising N, O, and S, wherein said heterocycle is linked to the structure according to formula 1 via a C atom or an N atom; and - a 5-membered to 11-membered spiro group which can optionally contain 1, 2, or 3 heteroatoms independently selected from among the group comprising N, O, and S, wherein said spiro group is linked to the structure according to formula 1 via a C atom or an N atom, wherein said group B can be optionally substituted as described in claim 1, and R3,R4,R5, R6, and m can have the meanings indicated in claim 1. The invention also relates to pharmaceutical compositions containing said compounds.
摘要翻译：本发明涉及式1的新的取代的萘啶，以及其药理学上可接受的盐，非对映体，对映体，外消旋体，水合物或溶剂合物，其中R 1是选自-O-R 3，-NR 3 R 4，-CR 3 R 4 R组成的组中选择的基团A 5 ， - （乙炔）-R 3，-S-R 3，-SO-R 3，和SO 2 -R 3或R 1是基团B选自的组中选择 - C6-10芳基， - 五到十元单环或双环杂芳基具有选自N，O和S的组中独立选择的1-3个杂原子; 其中所述杂芳基或者通过一个C原子或通过N原子连接的，具有以下结构的根据式1， - 三至具有从所述组独立地选自1-3个杂原子至十元单环或双环，饱和或部分饱和的杂环选自N，O和S，其中所述杂环或者通过一个C原子或通过N原子连接的，具有以下结构的根据式1，以及 - 5-至11-元螺环基团，任选地含有1,2或 3可以是选自N，O和S的组中独立选择的杂原子，所述螺环基团则通过一个C原子或通过N原子连接的，具有以下结构的根据式1，其中所述残基B是任选地作为可以如权利要求1，其中R3，R4，R5，R6和m可以具有权利要求1中所述的含义，以及含有这些化合物的药物组合物中所述被取代。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式